ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients

Cuffe, Sinéad; Azad, Abul Kalam; Qiu, Xiaoping; Qiu, Xin; Brhane, Yonathan; Kuang, Qin; Marsh, Sharon; Savas, Sevtap; Chen, Zhuo; Cheng, Dangxiao; Leighl, Natasha B.; Goss, Glenwood D.; Laurie, Scott A.; Seymour, Lesley; Bradbury, Penelope Ann; Shepherd, Frances A.; Tsao, Ming‐Sound; Chen, Bingshu E.; Xu, Wei; Liu, Geoffrey

doi:10.1016/j.canep.2015.12.012

Cited by 7 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Caucasian ABCC2 rs8187710 Adverse OS (Adjusted hazard ratio [aHR] 2.22; 95% CI: 1.2–4.0; p = 0.009) rs8187710 (4544G>A), have association to OS. [ 29 ] 15 103 Patients, Gastric Cancer Asian ABCC2 rs717620 TT and TC genotype have a better response of chemotherapy 3.80 times than CC genotype (95% CI: 1.27–11.32). Polymorphism of ABCC2-24C > T could be a clinical predictor factor of Platinum-Based Chemotherapy.…”

Section: Methodsmentioning

confidence: 99%

“…The proteins which are critical players in the metabolism of many chemotherapeutic agents and play a role in the mechanism of reducing drug accumulation include the Adenosine triphosphate-binding cassette transporter family and proteins that play a role in the detoxication process, such as glutathione S-transferase, organic cation transporter, and multidrug toxin extrusion. 25 , 28 , 29 , 77 , 78 …”

Section: Methodsmentioning

confidence: 99%

“…19 , 25 , 80 As listed in Table 1 , an ABCC2 polymorphism is associated with the overall survival of patients with advanced-stage NSCLC. 29 A polymorphism in ABCC2 (rs717620) resulting from an alteration of C to T is known to be related to neoadjuvant chemotherapy’s pathological response. Another study has indicated that this protein is related to the tumor regression grade (TRG) value.…”

Section: Methodsmentioning

confidence: 99%

“…It is clear that reduced drug levels at the target site will affect the formation of platinum-DNA adducts and decreases the efficacy, while alteration of elimination rate will be affected to level and severity of toxicity. [22][23][24][25][26][27][28][29] The pharmacodynamics mechanism includes increased damaged-DNA repair activity. The DNA repair mechanism's increased activity will result in failure to form DNA damage induced by platinum.…”

Section: Platinum-based Chemotherapy Resistancementioning

confidence: 99%

See 3 more Smart Citations

<p>Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review</p>

Afifah

Diantini

Intania³

et al. 2020

PGPM

View full text Add to dashboard Cite

Previous studies have indicated that genetic variations in individuals may result in changes in gene expression and amino acids. The effect of these changes may lead to different responses to platinum-based chemotherapy. A vast response rate interval and a short survival rate indicate that the efficacy and efficiency of the selection of chemotherapy have not been optimized. This article aims to illustrate the potential relationship of various genetic polymorphisms in response to platinum-based chemotherapy for several types of cancer. This review was conducted using articles from the last three-and five-year periods (2014-2019) that use gene polymorphism and its relationship to the efficacy of platinumbased chemotherapy as their theme. A total of 26 out of 488 relevant articles were included based on specific criteria. Through various mechanisms, genes, including ERCC1, ERCC2/ XPD,

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Platinum-based Chemotherapy Resistancementioning

confidence: 99%

See 2 more Smart Citations

<p>Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review</p>

Afifah

Diantini

Intania³

et al. 2020

PGPM

View full text Add to dashboard Cite

show abstract

“…Together with 1249G and 3972T, -24T haplotype was associated with imatinib resistance [ 89 ] . Regarding therapy using platinum or platinum-derivates, e.g., carboplatin, it was observed that 4544G>A (rs8187710) correlated with adverse survival rates of patients suffering from non-small cell lung cancer [ 90 ] . Furthermore, this SNP was associated with doxorubicin-induced cardiotoxicity requiring closer monitoring during treatment [ 59 ] .…”

Section: Multidrug Resistance In Cancer Treatment and Its Pharmacogen...mentioning

confidence: 99%

Germline variants in cancer therapy

Kaehler¹,

Cascorbi²

2019

CDR

View full text Add to dashboard Cite

Cancer pharmacogenetics implies a complex combination of germline variants from the patient and somatic mutations in tumor cells. Somatic mutations meanwhile have become drugable targets or biomarkers, whereas germline mutations potentially predict adverse drug effects or drug response. Here, we evaluate hereditary variants in biotransforming enzymes and drug transporters, such as thiopurine S-methyltransferase, UDP-glucuronosyltransferase (UGT1A1), dihydropyrimidine dehydrogenase (DPD), as well as ABC transporters (ABCB1 , ABCG2 and ABCC subfamily) with respect to cytostatics and targeted therapies. Furthermore, gene expression regulation with regards to epigenetics and posttranscriptional modification are discussed.

show abstract

Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum‐based doublet chemotherapy

Sharma

Singh

Sharma

2022

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background ABC transporters are membrane proteins expressed in the lungs and are crucial for efflux of various chemotherapeutic agents. Polymorphisms of ABC transporters have a certain impact on the transporter activity because their expression levels may influence the extent and longevity of chemotherapeutic drug outflow, affecting patient outcomes. The present study aimed to assess the impact of ABCB1, ABCC1/2, and ABCG2 gene variants in predicting prognosis and clinical outcomes in lung carcinoma patients. Methods In total, 502 lung cancer patients undergoing platinum‐based chemotherapy were recruited in this prospective study. Genotyping of ABCB1 (C1236T, C3435T, and G2677T/A), ABCC1 (G3173A and G2168A), ABCC2 (G4544A), and ABCG2 (C421A) polymorphisms in Northern Indian lung carcinoma patients were evaluated using polymerase chain reaction‐restriction fragment length polymorphism analysis. Results Poor survival outcomes were noted in patients carrying a heterozygous genotype (CT) for the ABCB1 C1236T polymorphism compared to the wild‐type genotype (CC) (p = 0.04). The mutant genotype (AA) for ABCC1 G3173A exhibited a lower median survival time compared to the reference genotype (GG) (p = 0.009). Lower survival was observed in individuals carrying a heterozygous genotype (GA) for ABCC2 G4544A polymorphism compared to the wild‐type genotype (GG) (p = 0.017). Small cell lung cancer patients with the ABCB1 G2677A polymorphism having a heterozygous genotype (GA) showed poor survival compared to the wild‐type genotype (GG) (p = 0.03). For ABCC1 G3173A, adenocarcinoma patients having a mutant genotype (AA) had reduced survival compared to the wild‐type (GG) genotype (p = 0.03). For ABCB1 C3435T, individuals carrying a heterozygous (CT) (p = 0.018) and mutant (TT) genotype (p = 0.007) had poor survival compared to the wild‐type (CC) genotype in patients treated with pemetrexed and cisplatin. The patients administered cisplatin and irinotecan and having mutant alleles (AA) for the ABCB1 G2677A polymorphism showed a lower survival compared to the individuals carrying wild‐type alleles (GG) (p = 0.009). Conclusions Our findings suggest that ABCB1 C1236T, ABCB1 C3435T, ABCB1 G2677A, ABCC1 G3173A, and ABCC2 G4544A are involved in predicting prognosis. Genotyping of the ABC polymorphism is essential for predicting prognosis in lung carcinoma patients.

show abstract

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients

Cited by 7 publications

References 43 publications

<p>Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review</p>

<p>Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review</p>

Germline variants in cancer therapy

Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum‐based doublet chemotherapy

Contact Info

Product

Resources

About